1110 Cell depleting agents assessment in preclinical models
1110 Cell depleting agents assessment in preclinical models
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundDepletion of undesired immune cells has shown to be a promising approach to treat cancer. B cell depleting antibodies such as Rituximab are often used to treat patients with lymphoma and has shown improved patients’ survival. Cell depletion can be triggered by antibody dependent cellular cytotoxicity (ADCC), antibody dependent cellular ph...
Alternative Titles
Full title
1110 Cell depleting agents assessment in preclinical models
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_6a043aa65f184ac19fc2830c2ef17f76
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6a043aa65f184ac19fc2830c2ef17f76
Other Identifiers
E-ISSN
2051-1426
DOI
10.1136/jitc-2023-SITC2023.1110
